Literature DB >> 8609112

Treatment of deformity of the lower limb in adults who have osteogenesis imperfecta.

D Ring1, J B Jupiter, P K Labropoulos, J J Guggenheim, D F Stanitsky, D M Spencer.   

Abstract

The Ilizarov method of lengthening was used to correct deformities of the lower extremity in six patients who had type-1 osteogenesis imperfecta, as categorized by Silence et al. The average age was thirty-one years (range, fourteen to fifty-one years). The deformities included shortening of four tibiae and three femora as well as an angular malalignment (average, 28 degrees; range, 20 to 40 degrees) of all four tibiae and one femur. One patient also had a non-union of the right femur. The average angular correction was 23 degrees (range, 20 to 30 degrees). The seven limb segments gained an average of 6.6 centimeters (range, two to eleven centimeters) in length. All limb-length discrepancies were corrected to within two centimeters of the length of the contralateral limb. At an average of three years and four months (range, one year and seven months to six years), the roentgenographic appearance of the fully matured bone was comparable with that of the original bone. There was no fractures or increases in the angulation of the segment of new bone. Two patients had pain when walking; it was related to a chronic pin-track infection in one and to osteoarthrosis of the ankle in the other. The functional status of four patients was improved and that of the other two patients was unchanged. All six patients were pleased with the outcome of the procedure. There was eighteen complications: stiffness of the knee in two patients; a peroneal nerve palsy in two; a superficial pin-track infection in three; and a deep pin-track infection, greater-than-normal loss of blood intraoperatively, loosening of two pins, worsening of the instability of the knee, and an infection in the knee in one patient each. In another patient, a Rush rod that had been placed before correction of the deformity migrated proximally and had to be removed after completion of the correction. There were five fractures.

Entities:  

Mesh:

Year:  1996        PMID: 8609112     DOI: 10.2106/00004623-199602000-00008

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  7 in total

1.  [Total knee replacement with ceramic femoral components: a national prospective multicenter study of clinical and radiological outcomes].

Authors:  P Bergschmidt; C Lohmann; D Ganzer; R Bader; S Finze; G Kundt; C Hauzeur; C Lukas; W Rüther; W Mittelmeier
Journal:  Orthopade       Date:  2011-03       Impact factor: 1.087

2.  Correction of Lower Limb Deformities Using Ilizarov's Technique.

Authors:  V P Pathania; A K Sharma; G R Joshi; John T John
Journal:  Med J Armed Forces India       Date:  2011-07-21

3.  Musculoskeletal manifestations of mild osteogenesis imperfecta in the adult.

Authors:  Fergus E McKiernan
Journal:  Osteoporos Int       Date:  2005-05-19       Impact factor: 4.507

4.  Comparison of the bone modeling effects caused by curved and straight nickel-titanium intramedullary nails.

Authors:  S Kujala; J Tuukkanen; T Jämsä; A Danilov; A Pramila; J Ryhänen
Journal:  J Mater Sci Mater Med       Date:  2002-12       Impact factor: 3.896

5.  Surgical treatment in Osteogenesis Imperfecta - 10 years experience.

Authors:  I Georgescu; C Vlad; T Ş Gavriliu; S Dan; A A Pârvan
Journal:  J Med Life       Date:  2013-06-25

Review 6.  Pain Phenotypes in Rare Musculoskeletal and Neuromuscular Diseases.

Authors:  Anthony Tucker-Bartley; Jordan Lemme; Andrea Gomez-Morad; Nehal Shah; Miranda Veliu; Frank Birklein; Claudia Storz; Seward Rutkove; David Kronn; Alison M Boyce; Eduard Kraft; Jaymin Upadhyay
Journal:  Neurosci Biobehav Rev       Date:  2021-02-10       Impact factor: 9.052

7.  Regenerate bone fracture rate following femoral lengthening in paediatric patients.

Authors:  N G Burke; A J Cassar-Gheiti; J Tan; G McHugh; B J O'Neil; M Noonan; D Moore
Journal:  J Child Orthop       Date:  2017-06-01       Impact factor: 1.548

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.